Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Safety and Adverse Events
研究概览
简要总结
This prospective, single-center, first-in-indication feasibility study will evaluate the safety and preliminary effectiveness of spinal cord stimulation (SCS) for the treatment of severe, treatment-refractory primary Restless Legs Syndrome (RLS). Participants will undergo implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System and will be followed for 24 months with clinical, neurophysiological, and patient-reported outcome assessments.
详细描述
Restless Legs Syndrome (RLS) is a chronic neurological disorder characterized by an urge to move the legs that disrupts sleep and quality of life. Current medical therapies often lose effectiveness over time or are associated with significant side effects. Preliminary case reports suggest that spinal cord stimulation (SCS) may improve RLS symptoms.
This single-arm feasibility study will enroll up to 15 adults with severe, treatment-refractory primary RLS. Participants will undergo baseline clinical, neuropsychological, and electrophysiological assessments followed by implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System. Follow-up evaluations will occur through 24 months post-activation. Primary outcomes focus on device and procedure safety. Secondary outcomes evaluate changes in RLS severity, patient-reported outcomes, neurophysiological biomarkers, and device utilization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >18 years and older.
- •Received a medical diagnosis of RLS via first screening with Cambridge Hopkins- RLS questionnaire and confirmed via Hopkins-Hening Diagnostic questionnaire.
- •IRLS Scale score ≥ 21 (classified as severe) and received a determination of treatment refractory RLS or inadequate response to standard medical treatment for RLS by a sleep medicine physician.
- •RLS symptoms occur ≥ 3 nights per week.
- •Willing and able to comply with study procedures.
- •Able to provide informed consent.
排除标准
- •Age <18 years.
- •Neuropathic pain, other than RLS on DN4 questionnaire.
- •Any mental or physical limitation that would prevent completing and of the study protocols.
- •Active medical implant in the body (i.e., pacemaker).
- •History of prior SCS trial or implantation.
- •Currently using another device to treat RLS.
- •Unable or unwilling to comply with study protocols.
- •Other medical conditions that would put the subject at risk as determined by the investigators.
- •Pregnant, breastfeeding, or trying to become pregnant.
- •Currently participating or plans to participate in any other investigational clinical evaluation during the study period that may, in the opinion of the investigators, affect RLS.
- •Ferritin < 50 ng/mL (excludes iron deficiency).
- •HgA1C > 7.5 (excludes unstable diabetes melilitus)
- •One or more of the following diagnoses: spinal cord injury or prior spinal surgery, severe peripheral neuropathy, severe psychiatric or cognitive disorder that may interfere with study participation, history of drug or alcohol abuse within the past year, epilepsy or seizure disorder, current active or chronic infection other than common cold, malignancy within the past 5 years (not including basal cell or squamous cell skin cancer), severe movement disorder (i.e., Parkinson's disease), deep vein thrombosis, multiple sclerosis, known or suspected allergy to SCS materials.
研究组 & 干预措施
SCS Implant
干预措施: Spinal Cord Stimulation (Device)
结局指标
主要结局
Safety and Adverse Events
时间窗: Baseline through 24 months
Frequency, severity, and relationship of device-, stimulation-, and procedure-related adverse events.
次要结局
- Change in International Restless Legs Syndrome Scale (IRLS)(Baseline through 24 months)
- Clinician Global Impression Improvement Scale (CGI-I)(Baseline through 24 months)
- Patient Global Impression of Improvement (PGI-I)(Baseline through 24 months)
- Suggested Immobilization Test (SIT)(Baseline through 24 months)
- PROMIS Sleep, Pain, Anxiety, Depression, Cognition, and Health Measures(Baseline through 24 months)
- Changes in Neurophysiological Measures of Spinal Cord Stimulation Response(Baseline through 24 months)
- Patient-Reported Outcomes Measurement Information System - Sleep(Baseline through 24 months)
- Patient-Reported Outcomes Measurement Information System - Pain(Baseline through 24 months)
- Patient-Reported Outcomes Measurement Information System - Anxiety(Baseline through 24 months)
- Patient-Reported Outcomes Measurement Information System - Depression(Baseline through 24 months)
- Patient-Reported Outcomes Measurement Information System - Cognition(Baseline through 24 months)
- Patient-Reported Outcomes Measurement Information System - Mental health battery(Baseline through 24 months)
- Patient-Reported Outcomes Measurement Information System - Physical Health Battery(Baseline through 24 months)
研究者
Marshall Holland
Assistant Professor of Neurosurgery
University of Alabama at Birmingham